CARDIOPROTECTIVE MECHANISMS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ISCHEMIC HEART DISEASE

Mualliflar

  • Mekhribon Khayrilloeva ##default.groups.name.author##
  • Nematulla Bobokambarov ##default.groups.name.author##
  • Buron Lapasov ##default.groups.name.author##

##semicolon##

To analyze the pharmacological mechanisms of cardioprotective action of empagliflozin in patients with T2DM and IHD

Annotatsiya

Type 2 diabetes mellitus (T2DM) significantly increases the risk of ischemic heart disease (IHD). Traditional hypoglycemic therapy often fails to reduce cardiovascular risk, which necessitates the use of drugs with proven cardioprotective effects

##submission.downloads##

##submissions.published##

2026-06-04

##issue.issue##

2026: INDICATORS OF LATENT COURSE OF HIV INFECTION AMONG YOUTH AND EPIDEMIOLOGICAL FACTORS AFFECTING EARLY DETECTION

Bo'lim

Articles